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diabetes and nephropathy.
Background. Diabetic nephropathy is the leading cause of
end-stage renal disease (ESRD). Anemia is common in diabet-
ics with nephropathy; however, the impact of anemia on pro-
gression to ESRD has not been carefully examined.
Methods. We studied the relationship between baseline
hemoglobin concentration (Hb) and progression of diabetic
nephropathy to ESRD in 1513 participants enrolled in Reduc-
tion in Endpoints in NIDDM with the Angiotensin II Antag-
onist Losartan study and followed for an average of 3.4 years.
Multivariate Cox proportional hazards models were used to an-
alyze the relationship between Hb and ESRD, after adjusting
for predictors for ESRD. Analyses were performed with Hb
stratified by quartile: first quartile <11.3 g/dL, second quartile
11.3 to 12.5 g/dL, third quartile 12.6 to 13.8 g/dL, and fourth
quartile ≥13.8 g/dL (reference) and as a continuous variable.
Results. Baseline hemoglobin concentration was correlated
with subsequent development of ESRD. After adjustment for
predictors of ESRD, the hazard ratios for the first, second, and
third Hb quartiles were 1.99 (95% CI, 1.34-2.95), 1.61 (95%
CI 1.08-2.41), and 1.87 (95% CI 1.25-2.80). With hemoglobin
as a continuous variable, the adjusted hazard ratio was 0.90
(95% CI 0.84-0.96, P =0.0013). The average increase in adjusted
relative risk was 11% for each 1 g/dL decrease in hemoglobin
concentration.
Conclusion. Our data suggest that even mild anemia, Hb
<13.8 g/dL increases risk for progression to ESRD. Hemoglobin
is an independent risk factor for progression of nephropathy to
ESRD in type 2 diabetes.
Diabetic nephropathy is a major public health prob-
lem in the United States. It is the leading cause of end-
stage renal disease (ESRD), accounting for nearly 50%
of all new cases at a cost of $6 billion per year, consum-
ing approximately 3% of the Medicare budget [1]. Risk
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factors for development and progression of diabetic kid-
ney disease include hypertension, poor glycemic control,
and levels of proteinuria. Lowering blood pressure and
using angiotensin-converting enzyme inhibitors and an-
giotensin receptor antagonists slow progression of dia-
betic nephropathy; however, these treatments do not stop
progression of disease to end-stage. One possibility for
continued progression of kidney disease is the presence
of unrecognized risk factors.
Anemia is common among patients with nephropa-
thy attributed to type 2 diabetes and is a known risk
factor for morbidity and mortality among patients with
ESRD [2–7]. Several small studies have suggested that
low hemoglobin concentration is a risk factor for pro-
gression of both diabetic and nondiabetic nephropathies.
However, these studies were limited by retrospective de-
sign, small numbers of enrollees, surrogate markers of
renal outcome, and short duration of follow-up [8–17].
In a preliminary analysis of the Reduction in Endpoints
in NIDDM with the Angiotensin II Antagonist Losartan
(RENAAL) study, hemoglobin at baseline was identified
as an independent predictor for progression of nephropa-
thy in participants with type 2 diabetes [18]. Because
there are therapeutic options for treatment of anemia,
we sought to evaluate anemia further as a risk factor for
ESRD in nephropathy attributed to type 2 diabetes.
METHODS
Study population
The RENAAL study was a prospective randomized,
multinational, double-blind, placebo-controlled trial of
1513 participants with type 2 diabetes and nephropathy
who were followed for an average of 3.4 years. The pri-
mary end point of RENAAL was the combined end point
of doubling of serum creatinine, ESRD, or death. The
study protocol was approved by the institutional review
board at each center, and all patients provided written
informed consent. The inclusion and exclusion criteria
and description of the RENAAL population have been
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reported. The RENAAL study demonstrated a renopro-
tective effect of losartan (Cozaar; Merck & Co., West
Point, Pa, USA) in type 2 diabetics with nephropathy,
beyond blood pressure control [19, 20].
Hematology/blood sampling
All baseline laboratory parameters in RENAAL were
determined prior to randomization [19]. Hemoglobin
concentration was chosen because it is the standard in-
dicator for anemia among those with chronic kidney dis-
ease (CKD) [21]. Baseline hemoglobin concentration was
determined for each patient from a single measurement.
Samples for hemoglobin analysis were collected in potas-
sium EDTA tubes at room temperature and analyzed
in regional reference laboratories. Hemoglobin measure-
ment was determined by photometric absorbance using
Coulter model GEN-S and STKS (Beckman Coulter,
Inc., Fullerton, CA, USA). Hemoglobin measurements
were cross-validated on a monthly basis using normal and
abnormal samples in the central laboratory.
End points
The principal end point for this analysis was ESRD
defined as the need for chronic dialysis or renal trans-
plantation. We also evaluated the composite end point of
ESRD or death because death is an important competing
event for patients with CKD [22, 23]. Death was defined
as death from any cause as prespecified in the RENAAL
study protocol [19]. For our analysis, if the participant
reached ESRD and died later in the study, ESRD was
counted as the end point.
Ascertainment of end points
One hundred percent of the participants could be ac-
counted for with respect to the end points of ESRD and
death. Households of participants who did not return for
follow-up visits were contacted by telephone to deter-
mine if the participants had started dialysis, undergone
renal transplant, or died. In some cases, further informa-
tion was obtained from the Centers for Medicare and
Medicaid Services for the ESRD end point, and from the
Social Security Administration Death Index for the death
end point. All study end points were adjudicated by an
independent Clinical Endpoint Classification Committee
blinded to the treatment arm of the study participant, in
accordance with study protocol [19].
Statistical analysis
In order to explore the relationship between
hemoglobin and end points, participants were catego-
rized by quartiles according to baseline hemoglobin con-
centration (Hb): first quartile <11.3 g/dL, second quartile
11.3 to 12.5 g/dL, third quartile 12.6 to 13.8 g/dL, and
fourth quartile ≥13.8 g/dL. The fourth quartile was desig-
nated as the reference quartile to which all other quartiles
were compared.
The baseline characteristics for participants were sum-
marized by Hb quartile with mean and standard devi-
ation for continuous variables and number and percent
for categorical variables. Trend tests were done between
Hb quartiles (independent variable) and each covariate
(dependent variable) using linear regression for contin-
uous variables, and the Cochran-Armitage test for trend
for categorical variables [24]. Each categorical variable
was dichotomized into a binary variable. For example,
for race, four binary variables were created: Asian ver-
sus non-Asian, black versus non-black, Hispanic versus
non-Hispanic, and white versus non-white.
Event curves depicting the percentage of patients ex-
periencing both ESRD and ESRD or death were esti-
mated by Hb quartile using the Kaplan-Meier procedure.
The risk for each end point was summarized by Hb
quartile and expressed as event rate in units of events
per 1000 patient-years of follow-up. The event rate per
1000 patient-years of follow-up was calculated as 1000 ×
(total number of patients with event)/(total number of
years until event or study termination). In addition, the
relative hazard risk (expressed as the hazard ratio) for
Hb for each end point was evaluated using Cox propor-
tional hazards models with Hb as a categorical variable
(quartiles) and as a continuous variable.
End-stage renal disease end point
Multivariate Cox regression models were utilized to
identify hemoglobin as an independent risk factor and to
explore the relationship between hemoglobin and ESRD.
Unadjusted Cox regression models were utilized to cal-
culate hazard ratios with respect to the highest Hb quar-
tile. Additional covariates for the primary multivariate
model were selected a priori based on scientific evidence
demonstrating influence on progression of kidney dis-
ease as follows: age, sex, race, body mass index, smoking,
systolic blood pressure (SBP), diastolic blood pres-
sure (DBP), serum creatinine, serum albumin, calcium,
phosphorus, total cholesterol, low-density lipoprotein,
triglycerides (natural log transformed), and proteinuria
(natural log transformed). In this model, categorical co-
variates were converted into binary indicators: male (=1)
versus female (=0), Asian (=1) versus non-Asian (=0)
and so on. Covariates from this list that were significant
on univariate analysis were entered into a multivariate
model. Backward selection was used to determine the sig-
nificant covariates with a = 0.01. Through this sequence,
four independent covariates were identified: Hb (either
as a continuous variable or by quartiles), serum creati-
nine, proteinuria, and serum albumin. Adjusted hazard
ratios were calculated with respect to the highest Hb
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quartile from a final multivariate model that included Hb
quartiles, proteinuria, serum creatinine, and serum albu-
min, the independent risk factors identified through this
process.
To explore our model further, we developed addi-
tional multivariate models with the following covariates
added to the above list of baseline covariates: estimated
glomerular filtration rate [21], baseline medical history
(amputation, angina, congestive heart failure, myocardial
infarction, neuropathy, and retinopathy), and randomiza-
tion to losartan. In the initial and additional multivariate
models for the end point of ESRD, the same four inde-
pendent covariates were identified: Hb, serum creatinine
(or estimated glomerular filtration rate), proteinuria, and
serum albumin. Randomization to losartan was also an
independent covariate when included in the model, but
did not change our conclusion.
End-stage renal disease or death end point
The same procedure was used to develop a separate
initial multivariate model for the end point of ESRD or
death, utilizing the a priori list of baseline covariates as
described for ESRD. Additional multivariate analyses for
ESRD or death were repeated with the following sets
of additional covariates: estimated glomerular filtration
rate, baseline medical history, and randomization to losar-
tan. For the ESRD or death end point, the initial and ad-
ditional models revealed the following independent risk
factors: Hb, serum creatinine (or estimated glomerular
filtration rate), proteinuria, and serum albumin. Hazard
ratios were calculated for the end point ESRD or death
from the final multivariate model with Hb quartiles, pro-
teinuria, serum creatinine, and serum albumin, the in-
dependent risk factors identified through this process.
Randomization to losartan was also an independent co-
variate when included in the model, but did not change
our conclusion.
Because Hb was not available for 45 of these partici-
pants, it was predicted through linear regression analysis
modeled on Hb, with available baseline covariates for all
participants. Other baseline covariates were not available
for 15 participants. Analyses excluding these 60 patients
(4%) were also conducted. Participants with missing data
at baseline were not randomly distributed across Hb quar-
tiles. Most of the participants with missing data at baseline
were in the third Hb quartile (46.7%), while few were in
the fourth Hb quartile (8.3%). In order to circumvent
the nonrandom nature of missing data at baseline, im-
putation was used to predict missing values as described
in order to include all participants in the analysis. The
above models were repeated while excluding 60 patients
with missing values at baseline, and similar results were
obtained for both end points. Statistical Analysis System
Version 8 (Cary, NC, USA) was used for all analyses.
RESULTS
Baseline characteristics
Participant characteristics by Hb quartile are shown in
Table 1. Overall, participants were older [60 ± 7 years old
(mean ± SD)], mostly male (63%), had elevated serum
creatinine (1.9 ± 0.5 mg/dL), and had significant protein-
uria measured as urine albumin/creatinine ratio (1810.6 ±
1735.4 mg/g). On average, participants had hypoalbu-
minemia, hypercholesterolemia, and hypocalcemia, and
were moderately overweight. Average SBP was 153 ±
19 mm Hg, and average DBP was 82 ± 10 mm Hg. Eigh-
teen participants were receiving erythropoietin. On trend
analysis (P < 0.05), female gender, African American
race, neuropathy, retinopathy, increasing SBP, phospho-
rus, proteinuria, and LDL were associated with lower Hb.
White race, smoking, myocardial infarction history, in-
creasing DBP, albumin, and calcium were associated with
higher Hb.
Hemoglobin distribution
Baseline hemoglobin for this study population is illus-
trated in Figure 1. Hb ranged from 6.8 g/dL to 18.0 g/dL,
with a mean and standard deviation of 12.5 ± 1.8 g/dL.
Median hemoglobin was 12.4 g/dL. Randomization to
losartan treatment was balanced in each quartile (49.2%
for the first quartile, 50.1% for the second quartile, 47.4%
for the third quartile, 51.6% for the fourth quartile). At
baseline, the mean hemoglobin concentration was 12.5 g/
dL in both the placebo group and the losartan group. Af-
ter 36 months, the average follow-up hemoglobin concen-
tration was lower in both the losartan group (11.9 g/dL)
and the placebo group (12.3 g/dL).
End-stage renal disease
The proportion of participants reaching ESRD over
time was significantly higher for those in the first, sec-
ond, and third Hb quartiles compared to those in the
fourth quartile (Fig. 2). Participants with lower Hb had
higher event rates for ESRD (Table 2). The event rates for
ESRD per 1000 patient-years of follow-up were 144.2 for
the lowest quartile, 84.5 for the second quartile, 75.6 for
the third quartile, and 27.6 for the fourth quartile. The
unadjusted hazard ratios were 5.87 (95% CI 4.03-8.55,
P < 0.001) for the lowest quartile, 3.25 (95% CI 2.19-
4.82, P < 0.001) for the second quartile, and 2.86 (95%
CI 1.91-4.28, P < 0.001) for the third quartile, compared
to the fourth quartile. After adjustment for other base-
line risk factors, the risk for ESRD in the first, second, and
third Hb quartiles was still significantly greater compared
to the fourth quartile (Table 2).
Addition of baseline estimated glomerular filtration
rate and components of the medical history, along with
prespecified covariates (see Methods) in the multivariate
model did not change the results. The multivariate model
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Table 1. Baseline clinical characteristics by quartile of hemoglobin concentrationa
Baseline hemoglobin quartile
P value
Quartile 1 Quartile 2 Quartile 3 Quartile 4 for trendc
Hb <11.3 g/dL 11.3–12.5 12.5–13.8 Hb ≥13.8 g/dL
Baseline characteristic N = 372 N = 368 N = 337 N = 391
Age years 59.0 ± 7.6 60.4 ± 7.6 60.9 ± 6.8 60.3 ± 7.6 0.014
Sex
Male no. (%) 144 (38.7) 214 (58.2) 236 (70.0) 331 (84.7) <0.001
Female no. (%) 228 (61.3) 154 (41.8) 101 (30.0) 60 (15.3) <0.001
Raceb
Asian no. (%) 84 (22.6) 52 (14.1) 44 (13.1) 59 (15.1) 0.0006
Black no. (%) 74 (19.9) 75 (20.4) 38 (11.3) 39 (10.0) <0.001
Hispanic no. (%) 78 (21.0) 69 (18.8) 66 (19.6) 60 (15.3) 0.063
White no. (%) 133 (35.8) 164 (44.6) 185 (54.9) 229 (58.6) <0.001
Sitting systolic BP mm Hg 155.0 ± 19.9 153.2 ± 19.2 152.5 ± 19.8 149.6 ± 18.4 <0.001
Sitting diastolic BP mm Hg 80.4 ± 10.6 81.5 ± 10.0 82.4 ± 10.7 84.8 ± 9.8 <0.001
Serum creatinine mg/dL 2.1 ± 0.5 1.9 ± 0.5 1.8 ± 0.5 1.7 ± 0.4 <0.001
Estimated GFR mL/min/1.73m2 33.3 ± 10.8 38.9 ± 12.0 41.0 ± 11.8 45.9 ± 11.5 <0.001
Serum albumin g/dL 3.6 ± 0.4 3.7 ± 0.4 3.8 ± 0.4 4.0 ± 0.4 <0.001
Calcium mg/dL 9.1 ± 0.5 9.3 ± 0.5 9.4 ± 0.5 9.5 ± 0.4 <0.001
Phosphorus mg/dL 4.2 ± 0.6 4.0 ± 0.6 3.8 ± 0.6 3.6 ± 0.6 <0.001
U albumin/creatinine mg/g 2210.5 ± 1905.8 1984.4 ± 1744.5 1810.6 ± 1735.4 1290.7 ± 1259.2 <0.001
Serum triglyceride mg/dL 191.2 ± 156.2 206.5 ± 158.4 247.0 ± 250.9 235.8 ± 188.8 <0.001
Total cholesterol mg/dL 230.3 ± 58.4 230.1 ± 56.3 228.5 ± 56.5 223.6 ± 51.6 0.089
LDL mg/dL 146.7 ± 49.0 142.7 ± 45.7 139.4 ± 44.8 139.2 ± 42.9 0.020
Smoking no. (%) 52 (14.1) 66 (18.0) 58 (17.2) 89 (22.8) 0.003
BMI kg/m2 29.3 ± 7.3 30.3 ± 6.5 29.3 ± 5.7 30.1 ± 5.6 0.268
Medical historyd
Amputation no. (%) 33 (8.9) 34 (9.2) 27 (8.0) 38 (9.7) 0.800
Angina no. (%) 32 (8.6) 33 (9.0) 38 (11.3) 33 (8.4) 0.854
Congestive heart failure no. (%) 22 (5.9) 24 (6.5) 15 (4.5) 17 (4.3) 0.209
Myocardial infarction no. (%) 34 (9.1) 46 (12.5) 52 (15.4) 57 (14.6) 0.014
Neuropathy no. (%) 216 (58.1) 181 (49.2) 161 (47.8) 175 (44.8) <0.001
Retinopathy no. (%) 286 (76.9) 245 (66.6) 196 (58.2) 210 (53.7) <0.001
N = Number of participants with measured hemoglobin concentration at baseline.
aPlus-minus values are mean ± standard deviation for continuous variables. Number and percent are reported for categorical variables. For each variable, the
percentages reflect the total number of patients for whom data were available, which may be less than the total number of patients in the quartile in some cases.
Hemoglobin quartiles are based on observed and calculated observations.
b19 patients with other race were excluded from race due to small sample size.
cLinear regression was performed for continuous variables by median of hemoglobin quartile, and Cochran-Armitage test for trend was performed for each
categorical variable by hemoglobin quartile. P < 0.05 is significant.
dObtained from patient medical history at baseline.
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Fig. 1. Hemoglobin distribution at baseline. This histogram illustrates
the distribution of hemoglobin at baseline. The y-axis shows the num-
ber of participants at each hemoglobin concentration, expressed as
frequency. Hemoglobin ranged from 6.8 to 18.0 g/dL, with mean
hemoglobin of 12.5 g/dL.
that included estimated glomerular filtration rate did not
significantly alter our results, nor did any of the compo-
nents of baseline medical history.
Because treatment with angiotensin receptor antag-
onists has been shown to lower hemoglobin in some
participants with chronic kidney disease, we conducted
an analysis incorporating treatment assignment to losar-
tan into our model in addition to the other prespecified
covariates [25, 26]. Although treatment assignment was
significant on multivariate analysis, it did not alter our
conclusion.
Hemoglobin modeled as a continuous variable was
an independent predictor of ESRD with an unadjusted
hazard ratio of 0.71 per g/dL of Hb (95% CI 0.67-0.76,
P < 0.001). The adjusted hazard ratio was 0.90 (95% CI
0.84-0.96, P = 0.0013).
End-stage renal disease or death
The proportion of participants reaching the combined
end point of ESRD or death over time was significantly
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Fig. 2. Kaplan-Meier curves showing the cumulative incidence of
events over the course of the study by quartiles of baseline hemoglobin
concentration for ESRD (A) and for ESRD or death (B). The range
of hemoglobin was as follows: 6.8 to 11.3 g/dL (quartile 1), 11.3 to 12.5
g/dL (quartile 2), 12.5 to 13.8 g/dL (quartile 3), and 13.8 to 18.0 g/dL
(quartile 4). Cumulative events are shown for each outcome within each
hemoglobin quartile. Comparisons are made to quartile 4 (the reference
quartile) in each panel. ∗Indicates P < 0.05.
higher for those in the first, second, and third Hb quartiles
compared to those in the fourth quartile (Fig. 2). Partic-
ipants with lower Hb had higher event rates for ESRD
or death (Table 2). The event rates for ESRD or death
per 1000 patient-years of follow-up were 204.8 for the
lowest quartile, 124.9 for the second quartile, 126.4 for
the third quartile, and 76.2 for the fourth quartile. The
unadjusted hazard ratios for the first, second, and third
quartiles were 2.96 (95% CI, 2.32-3.79, P < 0.001), 1.72
(95% CI 1.32-2.24, P < 0.001) and 1.72 (95% CI 1.32-
2.24, P < 0.001), compared to the fourth quartile. In the
unadjusted analysis, the hazard ratios for participants in
the first, second, and third Hb quartiles were significantly
greater than the hazard ratio for the fourth quartile. After
adjusting for covariates, the hazard ratios for participants
in the first, second, and third Hb quartiles were lower in
magnitude, but still greater compared to the fourth Hb
quartile. The hazard ratios for participants in the first Hb
quartile remained significantly different compared to the
fourth quartile, while hazard ratios for the second and
third quartiles were no longer significantly different from
the fourth quartile (Table 2). Adding estimated glomeru-
lar filtration rate or baseline medical history or losartan
use to the prespecified covariates in the multivariate anal-
ysis did not change our conclusion.
Hemoglobin modeled as a continuous variable was an
independent predictor of ESRD or death with an unad-
justed hazard ratio of 0.80 (95% CI 0.76-0.84, P < 0.001).
The adjusted hazard ratio was 0.95 (95% CI 0.90-0.99,
P = 0.035).
DISCUSSION
The principal new finding in this study is that anemia
is an independent predictor for progression to ESRD in
type 2 diabetics with nephropathy. The significant asso-
ciation between baseline hemoglobin concentration and
progression to ESRD was present both when hemoglobin
was analyzed by quartiles and as a continuous vari-
able. After adjustment for risk factors for progression
of nephropathy, the risk for ESRD was increased even at
modest reduction in Hb, that is, below 13.8 g/dL. More-
over, the risk for ESRD nearly doubled (HR 1.99) for
participants in the lowest Hb quartile (<11.8 g/dL) com-
pared to those in the highest Hb quartile (≥13.8 g/dL).
The adjusted relative risk for ESRD increased by 11%
for each 1 g/dL decline in Hb. We also found that the risk
for the combined end point of ESRD or death was signif-
icantly greater for participants in the lowest Hb quartile,
compared to those in the highest Hb quartile. The ad-
justed relative risk for ESRD or death increased by 5.6%
for each 1 g/dL decline in Hb.
A key question is whether the association of low
hemoglobin concentration at baseline and subsequent
development of ESRD or death is caused by low
hemoglobin or low glomerular filtration rate. Our anal-
ysis cannot establish causality. However, we controlled
for level of renal function in two ways. First, we con-
ducted a multivariate analysis using serum creatinine as
a marker of renal function. In this analysis, Hb was an
independent risk factor for ESRD and the combined end
point of ESRD or death. In a separate model in which
we used estimated glomerular filtration rate as a mea-
sure of renal function at baseline, we found the same
result. Hemoglobin concentration at baseline was an in-
dependent predictor of ESRD and the risk for ESRD
was increased even at a modest reduction in hemoglobin
concentration.
We also conducted a separate analysis that included
components of medical history at baseline as covariates.
Medical history at baseline was collected based on patient
recall and physician input, and also at times, chart review.
Given the variability of the sources of information, it is
likely that these histories were not collected as carefully
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as outcomes data during the RENAAL study (i.e., adju-
dicated by an outcomes committee). Therefore, compo-
nents of medical history at baseline were not considered
in the primary analysis along with baseline characteristics.
We constructed a multivariate model that included
treatment assignment to losartan as well. This additional
model was constructed to evaluate the possibility that
losartan assignment would influence the results of our
analysis. By definition, baseline data were collected prior
to randomization to drug or placebo. In the additional
multivariate model that included treatment assignment to
losartan, our conclusion regarding hemoglobin concen-
tration was the same. Therefore, treatment with losartan
does not appear to be the explanation for the relation-
ship between baseline Hb and ESRD, or the combined
end point of ESRD or death in our analysis. As noted
above, adjustment for treatment assignment to losartan
did not alter the relationship between Hb and outcomes
in our study. Losartan use was balanced in each quartile.
Other investigators have shown that angiotensin recep-
tor blockers can cause anemia [26]. Both losartan and
placebo groups had a mean hemoglobin concentration of
12.5 g/dL at baseline, and lower mean hemoglobin con-
centration at 36 months: 11.9 g/dL in the losartan group
and 12.3 g/dL in the placebo group.
Gender is significantly associated with each end point
in univariate analysis. Lower hemoglobin in adult women
has been well described, and in RENAAL, women had
greater proteinuria than men. Therefore, in the mul-
tivariate analysis, when adjusting for both proteinuria
and hemoglobin, the significance of gender becomes
much weaker. After adjusting for significant risk factors,
the risk across Hb quartiles is similar for men and for
women.
Previous investigations examining the potential impact
of anemia on progression of renal disease were limited by
heterogeneous causes of kidney disease, small numbers
of participants, short duration of follow-up, and lack of
well-defined end points [8–17]. Moreover, none of these
studies examined the impact of anemia on ESRD; rather,
these studies utilized outcomes such as serum creatinine,
the inverse of serum creatinine, and clearance of iotha-
lamate, inulin, or para-amino hippuric acid. Our study
controlled for proteinuria and other factors associated
with progression of nephropathy. Furthermore, we eval-
uated the association between anemia and ESRD in a
well-defined population of 1513 participants with type 2
diabetes and nephropathy followed for an average for
3.4 years, the longest renal end point trial to date. Our
patient population of patients with type 2 diabetes and
nephropathy reflects a far more homogeneous disease
process than in prior studies. Our findings demonstrate
that higher baseline hemoglobin was independently as-
sociated with longer time to ESRD in participants with
type 2 diabetes and nephropathy.
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Anemia may begin in early stages of CKD [27, 28].
Furthermore, the number of individuals with CKD in the
United States is currently estimated at 19.2 million [27].
Moderate anemia (hematocrit <30) at incident dialysis is
associated with higher hospitalization rates, cost of care
[29, 30], and increased mortality [31]. Anemia is also a
major risk factor for cardiac morbidity and mortality for
participants with CKD [2, 3, 4, 6, 22, 31, 32–35]. In fact,
congestive heart failure (CHF) is the leading cause of
cardiac morbidity and mortality in diabetics, and anemia
and CHF coexist in the CKD population [1, 36, 37].
Treatment of anemia with erythropoietin improves
quality of life, reduces risk of progression to left ventric-
ular hypertrophy in predialysis CKD patients, and de-
creases hospitalization in ESRD [6, 7, 38]. However, less
than 30% of anemic pre-ESRD patients are treated for
anemia [39–41]. Because only 18 of 1513 participants in
our study were receiving erythropoietin, we were unable
to ascertain the impact of correction of anemia with ery-
thropoietin on ESRD and death outcomes. This low rate
of anemia treatment reflects uncommon use of this drug
during the time of the study (before 2001).
Current National Kidney Foundation guidelines for
pre-ESRD participants recommend treatment to a goal
Hb of 11 to 12 g/dL [42]. Our data suggest that even mild
anemia, Hb <13.8 g/dL, increases risk for progression
to ESRD. Whether treatment or prevention of anemia
may improve outcomes among those with type 2 dia-
betes and nephropathy remains to be determined. Cur-
rent trials of anemia treatment in CKD are following pa-
tients for cardiovascular and renal outcomes (Cardiovas-
cular Risk Reduction by Early Anemia Treatment with
Epoetin beta, Correction of Hemoglobin and Outcomes
In Renal Insufficiency, Trial to Reduce Cardiovascular
Events with Aranesp) [43–45].
The mechanism by which anemia might increase risk
for ESRD in diabetic nephropathy is unknown. Anemia
could aggravate fibrosis in the failing kidney by causing
renal tissue hypoxia. Renal hypoxia is known to stimulate
cytokines such as hypoxia inducing factor-1, which con-
tribute to renal scarring [46]. In addition, hypoxia stimu-
lates renal sympathetic activity, resulting in reduction in
renal blood flow and glomerular filtration rate over time
[47]. Finally, anemia may induce or exacerbate underly-
ing cardiac disease, which may in turn lead to worsening
renal function and hasten ESRD. Additional studies to
evaluate these or other mechanisms in participants with
nephropathy and diabetes are needed to determine how
anemia contributes to progression of kidney disease to
end-stage.
Limitations to our study include the fact that the
RENAAL study was not specifically designed to evaluate
the impact of anemia on progression of nephropathy. The
clear and consistent relationship between hemoglobin
and renal end points in the present study cannot prove
cause and effect. However, our findings add to those of
others who suggest that anemia may contribute to pro-
gression of CKD [8], and that decreasing kidney func-
tion is associated with a higher prevalence of anemia
[48]. In addition, our analysis could not evaluate the
mechanism of anemia in participants with progression in
diabetic nephropathy. Laboratory data regarding other
factors related to anemia, such as nutritional deficiencies
of iron, B12, or folate, iron saturation, red blood cell sur-
vival, hemoglobin electrophoresis, expression of hypoxia-
inducible factor, and toxic metabolites of uremia were
not obtained. Furthermore, specific anemia-related his-
tory, such as hemolysis, menorrhagia, or gastrointestinal
hemorrhage was not collected. We cannot exclude the
possibility that an unmeasured additional confounding
variable may explain our observation. Still, we adjusted
for risk factors for progression of diabetic nephropathy, as
well as preexisting cardiovascular disease and treatment
assignment to losartan.
CONCLUSION
Our data identify mild anemia (Hb <13.8 g/dL) as an
independent predictor of ESRD in type 2 diabetics with
nephropathy, and more severe anemia (Hb <11.3 g/dL)
as a predictor of ESRD or death. Because anemia in pa-
tients with diabetic nephropathy is a modifiable risk fac-
tor and can be treated and theoretically prevented by
administration of erythropoietin, further studies on the
relationship between anemia and progression of kidney
disease in patients with type 2 diabetes are warranted.
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